¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.

ABSTRACT: Immune checkpoint inhibitors (ICIs) are now commonly used to treat patients with metastatic malignant melanoma. Although concerns have been raised that the inflammatory response induced by ICIs may limit the ability of ¹⁸F-FDG PET/CT to assess tumor response, systematic analyses on the use of ¹⁸F-FDG PET/CT in this setting are mostly lacking. Thus, we set out to evaluate the association between tumor response on ¹⁸F-FDG PET/CT and prognosis in patients with metastatic malignant melanoma treated with ipilimumab. Methods: We analyzed 60 consecutive patients with metastatic melanoma who underwent ¹⁸F-FDG PET/CT scans both before and after treatment to evaluate treatment response after completion of ipilimumab therapy. Tumor response was asses

SUBMITTER: Ito K 

PROVIDER: S-EPMC6424231 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature